Mouse CRC tissues were used for the establishment of tumoroids and CRISPR/Cas9-mediated MEX3A knockout was performed in patient-derived CRC tumoroids to further understand its biological and therapeutic relevance. The gene discussed is MEX3A; the disease is colorectal carcinoma.